Microbicides: latest news

Microbicides resources

  • Microbicides

    Microbicides are any substances which protect people against infection by microbes, such as viruses or bacteria, on contact with those microbes....

    From: Preventing HIV

    Information level Level 4
  • Microbicides

    A microbicide is a topical agent that, when applied to a mucosal surface, serves as a barrier to infection. Microbicides can come in the form of...

    From: HIV transmission & testing

    Information level Level 4

Microbicides features

Microbicides news from aidsmap

More news

Microbicides news selected from other sources

  • ASPIRE Phase III trial of a vaginal ring for HIV prevention completes enrollment of 2,629 women

    MTN’s trial testing dapivirine ring on track to finish next year; IPM’s sister Phase III trial ongoing.

    30 June 2014 | Microbicide Trials Network
  • Rectal tenofovir gel yields much higher rectal and vaginal levels than oral tenofovir

    Tenofovir 1% gel applied rectally yielded rectal tissue concentrations orders of magnitude greater than those achieved with oral tenofovir, according to results of an 18-person study by US researchers. Systemic tenofovir exposure was lower with 1% gel than with oral tenofovir, but vaginal exposure was greater with the rectal gel.

    02 June 2014 | NATAP
  • IPM Receives Worldwide Rights to HIV Prevention Medicines

    The International Partnership for Microbicides (IPM) announced today that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

    09 May 2014 | International Partnership for Microbicides
  • Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum

    Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections in both the vagina and rectum in animals: HIV, herpes simplex virus 2, and human papillomavirus.

    22 April 2014 | Eurekalert Medicine & Health
  • Study: In two-drug, HIV-preventing vaginal ring, only one drug does the job

    The National Institutes of Health has shown that a study of its vaginal ring for the prevention of HIV came back with mixed results. The ring, which delivers two drugs, was safe for 28 days, but only one of the antiretroviral drugs was effective in protecting against the virus.

    10 March 2014 | Fierce Drug Delivery
  • New Rings, Gels, and Films Show Promise in Microbicide Trials

    Experimental vaginal microbicides—products such as gels, films, or flexible rings worn inside the vagina—were the focus of two studies reported Tuesday at the 21st Conference on Retroviruses and Opportunistic Infections.

    05 March 2014 | BETA blog
  • Study comparing injectable contraceptives DMPA and NET-EN finds HIV risk higher with DMPA

    Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE. The new analysis, conducted by researchers from the NIH-funded Microbicide Trials Network, is the first head-to-head observational study to directly compare differences in HIV risk between users of DMPA and NET-EN.

    04 March 2014 | Eurekalert Medicine & Health
  • Janssen Announces New Group Targeting Unmet Global Health Needs

    Janssen GPH will be responsible for clinical and product development and creating and implementing innovative new access strategies for a growing portfolio of pharmaceuticals, diagnostics, and services for diseases significantly impacting resource-limited countries and emerging markets, and includes bedaquiline for drug-resistant TB, long-lasting injectable rilpivirine for HIV prevention and the dapivirin ring for HIV prevention.

    22 January 2014 | Janssen press release
  • USAID, Population Council agreement for non-antiretroviral microbicide quest looks to expand prevention toolbox

    An agreement between the United States Agency for International Development and the Population Council announced Monday for the development of a non-antiretroviral-based compound to block HIV and other sexually transmitted infections could yield a low-risk, easy access product for women in low resource settings in as few as a dozen years, if a promising new compound performs as hoped. That is a big if - the field of microbicide research has seen a roller coaster of raised expectations and dashed hopes over the last decades.

    11 January 2014 | Science Speaks
  • AAPS showcases vaginal ring with tenofovir + contraceptive, gel suitable for vaginal and rectal use

    A new intravaginal ring delivers both tenofovir for HIV prevention and levonorgestrel for contraception for 3 months, researchers reported at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition taking place this week in San Antonio. Other studies looked at a novel gel for both vaginal and rectal use containing the antiretroviral IQP-0528, and a bio-adhesive vaginal gel combining tenofovir and the anti-herpes drug acyclovir.

    21 November 2013 | HIVandHepatitis.com
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.